Pomegranates, berries and walnuts contain only its precursors (ellagitannins), which gut bacteria convert to urolithin A in a two-step metabolism. That is why it has to be supplied as a high-purity ingredient.
Cohort studies show that the share of people who produce only urolithin A (the UM-A metabotype) falls from about 80% in childhood to about 55% after age 40, and around 10% of people produce none at all. The target population is precisely the group whose own production is declining.
Mechanistic studies have been published in Nature Medicine, Nature Metabolism and other journals; the scientific foundation of the category continues to be built by the global research community.
Disclaimer: this mechanism and its associated efficacy claims may not be used commercially without authorisation from the patent holder; Taiyi Health does not hold the corresponding patents.
Taiyi Health's Science Department has completed research on a new urolithin A pathway; patent filing in progress